Doctor profile · Federal record

Dr. Mark Lehman, MD

Dermatology Physician (CMS: Dermatology) · Tulsa, OK

  • NPI 1932195815
  • Accepts Medicare
  • MIPS 100.0 / 100 · 2023
  • 34 yrs in practice
  • Male
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
2121 E 21St St
Tulsa, OK 741141409
(918) 749-2261
fax (918) 749-8712
Mailing address
Po Box 52588
Tulsa, OK 741520588

Credentials & registration

NPPES · NUCC
NPI registered
September 2005 — 21 yrs on file
Profile last updated
May 16, 2008
Year of graduation
1992 — 34 yrs since
Specialty taxonomy
207N00000X — NUCC code
State license (1)
Oklahoma #19733
Medicaid
OK #100157070A

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1932195815. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
9,539
Distinct HCPCS
10
Medicare allowed
$508,683
HCPCS Description Services Patients Avg allowed
17003 Destruction of precancer skin growth, 2-14 growths 3,815 648 $6
99213 Established patient office or other outpatient visit, 20-29 minutes 2,111 1,208 $85
17000 Destruction of precancer skin growth, 1 growth 1,407 863 $50
17110 Destruction of skin growth, 1-14 growths 665 481 $101
99214 Established patient office or other outpatient visit, 30-39 minutes 504 363 $121
11102 Biopsy of related skin growth, first growth 270 234 $84
99203 New patient office or other outpatient visit, 30-44 minutes 110 110 $105
99212 Established patient office or other outpatient visit, 10-19 minutes 88 86 $53
17004 Destruction of precancer skin growth, 15 or more growths 78 51 $157
17262 Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm 61 53 $155

In context: peer comparison

Among 10 peers in Tulsa Dermatology Physician, average services per provider: 240. This provider delivers 40× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$3,065
Transactions
148
Manufacturers
15
Payer (manufacturer) Industry Txns Amount
Abbvie INC. 27 $600.74
Regeneron Healthcare Solutions, INC. 10 $241.14
E.R. Squibb & Sons, L.L.C. 14 $229.79
Janssen Biotech, INC. 13 $214.37
Novartis Pharmaceuticals Corporation 12 $212.18
Amgen INC. 7 $191.66
Lilly USA, LLC 12 $182.87
Sun Pharmaceutical Industries INC. 8 $171.60
Arcutis Biotherapeutics, INC. 14 $163.48
Incyte Corporation 11 $155.12
Dermavant Sciences, INC. 7 $119.37
Ucb, INC. 1 $111.91
Ortho Dermatologics, A Division of Bausch Health US, LLC 5 $100.15
Leo Pharma INC. 4 $84.12
Mayne Pharma Commercial LLC 3 $69.62

By nature of payment

Food and Beverage
$3,065

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
1,319
Patients
760
Total drug cost
$41,043
Drug Type Claims Patients Total cost
Triamcinolone Acetonide Generic 292 179 $3,327
Ketoconazole Generic 153 78 $3,821
Hydrocortisone Generic 141 95 $942
Betamethasone Dipropionate Generic 139 70 $7,768
Metronidazole Generic 117 69 $7,916
Fluocinonide Generic 74 39 $6,253
Mometasone Furoate Generic 71 51 $1,709
Mupirocin Generic 70 52 $719
Valacyclovir (Valacyclovir Hcl) Brand 66 27 $1,625
Cephalexin Generic 48 27 $396

Frequently asked questions

Auto-generated from federal data
What is Dr. Mark Lehman's medical specialty?
Dr. Mark Lehman practices Dermatology Physician in Tulsa, OK.
Where does Dr. Mark Lehman practice?
Dr. Mark Lehman practices at 2121 E 21St St, Tulsa, OK 741141409. Office phone: 9187492261.
What is Dr. Mark Lehman's NPI?
Dr. Mark Lehman's National Provider Identifier (NPI) is 1932195815, issued by NPPES.
Does Dr. Mark Lehman accept Medicare assignment?
Yes. Dr. Mark Lehman accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Mark Lehman commonly perform?
Top Medicare-reported procedures in 2023: Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Established patient office or other outpatient visit (HCPCS 99213); Destruction of precancer skin growth, 1 growth (HCPCS 17000). Source: CMS Medicare Physician & Other Practitioners file.